Additionally, as CCN2 is involved in various pathologies with elevated fibrotic processes, including Duchenne muscular dystrophy, pancreatic adenocarcinoma, and pulmonary fibrosis, ongoing clinical trials of anti-CCN2 therapies may provide further insights into its therapeutic potential across different conditions. Here, CCN2 is linked to pulmonary fibrosis.